Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Ballard CG, Kreitzman DL, Isaacson S, Liu IY, Norton JC, Demos G, Fernandez HH, Ilic TV, Azulay JP, Ferreira JJ, Abler V, Stankovic S; 015 Study Group.
Ballard CG, et al. Among authors: fernandez hh.
Parkinsonism Relat Disord. 2020 Aug;77:100-106. doi: 10.1016/j.parkreldis.2020.06.026. Epub 2020 Jun 28.
Parkinsonism Relat Disord. 2020.
PMID: 32712560